Vaxcyte, Inc. (PCVX)
NASDAQ$74.11+1.09 (1.49%)
Market Cap
$9.4B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
771 of 924
Rank in Industry
434 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PCVX Insider Trading Activity
PCVX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $51,905,101 | 63 | 100 |
Related Transactions
| Loxam Teri | director | 0 | $0 | 2 | $1.26M | $-1.26M |
| Gilbert Halley E | director | 0 | $0 | 1 | $1.33M | $-1.33M |
| Cowan Elvia | SVP, FINANCE | 0 | $0 | 3 | $1.36M | $-1.36M |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | 0 | $0 | 13 | $4.18M | $-4.18M |
| Wassil Jim | CHIEF OPERATING OFFICER | 0 | $0 | 13 | $7.8M | $-7.8M |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | 0 | $0 | 12 | $12.03M | $-12.03M |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 0 | $0 | 19 | $23.95M | $-23.95M |
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine …
Insider Activity of Vaxcyte, Inc.
Over the last 12 months, insiders at Vaxcyte, Inc. have bought $0 and sold $51.91M worth of Vaxcyte, Inc. stock.
On average, over the past 5 years, insiders at Vaxcyte, Inc. have bought $41.38M and sold $37.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 186,000 shares for transaction amount of $2.98M was made by Hopfner Robert Lorne (director) on 2020‑06‑16.
List of Insider Buy and Sell Transactions, Vaxcyte, Inc.
| 2025-03-05 | Sale | Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | 5,000 0.0037% | $70.74 | $353,699 | -2.42% | |
| 2025-03-03 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 8,000 0.0063% | $73.27 | $586,165 | 0.00% | |
| 2025-02-18 | Sale | GUGGENHIME ANDREW | PRESIDENT AND CFO | 8,000 0.0064% | $83.85 | $670,823 | -11.90% | |
| 2025-02-05 | Sale | Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | 5,000 0.0042% | $90.07 | $450,369 | -9.60% | |
| 2025-02-03 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 8,000 0.0063% | $86.22 | $689,790 | -3.69% | |
| 2025-01-21 | Sale | GUGGENHIME ANDREW | PRESIDENT AND CFO | 8,000 0.0063% | $86.51 | $692,101 | -4.83% | |
| 2025-01-15 | Sale | Loxam Teri | director | 6,250 0.0048% | $85.11 | $531,963 | -5.92% | |
| 2025-01-06 | Sale | Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | 5,000 0.004% | $85.58 | $427,923 | -2.36% | |
| 2025-01-02 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 8,000 0.0064% | $83.66 | $669,267 | +0.84% | |
| 2024-12-18 | Sale | GUGGENHIME ANDREW | PRESIDENT AND CFO | 8,000 0.0066% | $88.78 | $710,249 | -1.57% | |
| 2024-12-09 | Sale | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 2,366 0.0019% | $92.25 | $218,253 | -7.53% | |
| 2024-12-05 | Sale | Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | 5,000 0.0041% | $91.49 | $457,434 | -5.26% | |
| 2024-12-02 | Sale | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 15,000 0.0121% | $92.45 | $1.39M | -6.37% | |
| 2024-12-02 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 8,000 0.0064% | $92.49 | $739,885 | -6.37% | |
| 2024-11-18 | Sale | GUGGENHIME ANDREW | PRESIDENT AND CFO | 8,000 0.0064% | $85.81 | $686,518 | -0.58% | |
| 2024-11-07 | Sale | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 2,250 0.0019% | $103.80 | $233,558 | -15.75% | |
| 2024-11-05 | Sale | Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC | 5,000 0.0041% | $106.36 | $531,803 | -19.50% | |
| 2024-11-01 | Sale | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 15,000 0.0123% | $106.82 | $1.6M | -19.16% | |
| 2024-11-01 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 8,000 0.0065% | $106.80 | $854,423 | -19.16% | |
| 2024-10-18 | Sale | GUGGENHIME ANDREW | PRESIDENT AND CFO | 42,000 0.0344% | $115.39 | $4.85M | -24.18% |
Total: 217
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| TPG Group Holdings (SBS) Advisors, Inc. | 5074574 3.941% | $370.55M | 1 | 1 | <0.0001% | |
| EMSTER KURT VON | director | 4168718 3.2375% | $304.4M | 1 | 0 | <0.0001% |
| Heron Patrick J | director | 2309554 1.7937% | $168.64M | 1 | 0 | <0.0001% |
| Hopfner Robert Lorne | director | 1405418 1.0915% | $102.62M | 1 | 21 | <0.0001% |
Historical Insider Profitability vs. Competitors
$961,890,236 | 276 | 22.46% | $13.1B | |
$159,914,414 | 243 | 18.52% | $5.79B | |
$211,610,344 | 91 | 38.45% | $7.13B | |
$2,765,836 | 72 | 20.00% | $13.47B | |
$108,876,545 | 67 | 72.81% | $7.52B |
PCVX Institutional Investors: Active Positions
| Increased Positions | 202 | +59.76% | 18M | +13.34% |
| Decreased Positions | 152 | -44.97% | 14M | -10% |
| New Positions | 60 | New | 2M | New |
| Sold Out Positions | 63 | Sold Out | 5M | Sold Out |
| Total Postitions | 388 | +14.79% | 141M | +3.34% |
PCVX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Fmr Llc | $955,952.00 | 10.15% | 13.09M | -3M | -17.14% | 2024-12-31 |
| Vanguard Group Inc | $873,442.00 | 9.27% | 11.96M | +521,204 | +4.56% | 2024-12-31 |
| Blackrock, Inc. | $810,965.00 | 8.61% | 11.11M | +439,632 | +4.12% | 2024-12-31 |
| Janus Henderson Group Plc | $772,213.00 | 8.2% | 10.58M | -346,533 | -3.17% | 2024-12-31 |
| Ra Capital Management, L.P. | $634,485.00 | 6.74% | 8.69M | 0 | 0% | 2024-12-31 |
| Capital Research Global Investors | $453,492.00 | 4.81% | 6.21M | +1M | +26.79% | 2024-12-31 |
| State Street Corp | $331,467.00 | 3.52% | 4.54M | +1M | +33.29% | 2024-12-31 |
| Wellington Management Group Llp | $324,502.00 | 3.45% | 4.44M | -69,744 | -1.54% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $289,667.00 | 3.08% | 3.97M | -499,181 | -11.18% | 2024-12-31 |
| Goldman Sachs Group Inc | $228,524.00 | 2.43% | 3.13M | +2M | +229.69% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.